- Scott Myers described how PDAOAI searches and organizes an index of approximately 29 million PubMed abstracts to support focused biomedical research.
- Saran Saund presented a four-gene HCC signature associated with survival in an exploratory discovery analysis and an independent Japanese cohort.
- BIO REBOOT connects the platform’s research capabilities with potential funding and development support for selected projects.
Oncotelic Therapeutics Inc. (OTCQB: OTLC) (“Oncotelic”) is pursuing a development strategy that connects biomedical literature analysis with the practical work of developing therapeutics. At Drug Discovery 2026 in Burlingame, California, Scott Myers and Saran Saund showed how the company’s PDAOAI platform can help researchers organize scientific evidence and develop hypotheses for further investigation.
Myers, Oncotelic’s Product Manager, presented “The Infinity Problem: AI Search Aggregation for Biomedical Knowledge Discovery in Drug Development” on October 7. Saund, Chief Business Officer, followed on October 8 with an HCC case study describing how disease-specific literature analysis led to a four-gene mTOR-related signature associated with…
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
